Post-earnings recap
Reported
Tue, May 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Supernus Pharmaceuticals reported a strong earnings per share figure that exceeded expectations, indicating solid performance in that area. However, the stock reacted negatively, declining by 1.0%. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.49 | N/A | +41.88% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.